Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including  egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy in women with uterine fibroids or endometriosis.

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

Data Provided by Refinitiv. Minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
August 5, 2022
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
July 27, 2022
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
July 18, 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Events

SEC Filings

Filing date Description Form View

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.INS - XBRL INSTANCE DOCUMENT